Difference between revisions of "Venlafaxine-moclobemide"
From Psychiatrienet
(Created page with '{{Drugswitch | from = venlafaxine | to = moclobemide | stop = * '''Day 0:''' gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day. * '''Day 1:''' reduce a dosage...') |
|||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
| to = moclobemide | | to = moclobemide | ||
| stop = | | stop = | ||
| − | + | {{Generaldecrease25p3d}} | |
| − | + | {{7dWashout}} | |
| − | |||
| start = | | start = | ||
| − | + | {{MAOIncrease25p}} | |
| − | + | | caveat = | |
| − | | | + | {{caveSS}} |
| − | + | }} | |
| − | |||
Latest revision as of 14:04, 16 June 2016
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from venlafaxine to moclobemide.[1] [2]
Stop venlafaxine - Decrease with about 25% of original dose every 3 days
- Stop and wait 7 days for washout
Start moclobemide- Start at the first day after the washout period with about 25% of target dose.
Cave- Occurrence of the serotonin syndrome is possible without wash-out period.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
